# Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive

> **NCT03790397** · — · COMPLETED · sponsor: **Fundación GECP** · enrollment: 169 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT03790397
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-26
- **Primary completion:** 2019-07-15
- **Final completion:** 2020-04-01
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03790397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03790397, "Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03790397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*